#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Brain connectivity changes occurring following cognitive behavioural therapy for psychosis predict long-term recovery Little is known about the psychobiological mechanisms of cognitive behavioural therapy for psychosis (CBTp) and which specific processes are key in predicting favourable long-term outcomes.
1-1	0-5	Brain	_
1-2	6-18	connectivity	_
1-3	19-26	changes	_
1-4	27-36	occurring	_
1-5	37-46	following	_
1-6	47-56	cognitive	_
1-7	57-68	behavioural	_
1-8	69-76	therapy	_
1-9	77-80	for	_
1-10	81-90	psychosis	_
1-11	91-98	predict	_
1-12	99-108	long-term	_
1-13	109-117	recovery	_
1-14	118-124	Little	_
1-15	125-127	is	_
1-16	128-133	known	_
1-17	134-139	about	_
1-18	140-143	the	_
1-19	144-160	psychobiological	_
1-20	161-171	mechanisms	_
1-21	172-174	of	_
1-22	175-184	cognitive	_
1-23	185-196	behavioural	_
1-24	197-204	therapy	_
1-25	205-208	for	_
1-26	209-218	psychosis	_
1-27	219-220	(	_
1-28	221-225	CBTp	_
1-29	226-227	)	_
1-30	228-231	and	_
1-31	232-237	which	_
1-32	238-246	specific	_
1-33	247-256	processes	_
1-34	257-260	are	_
1-35	261-264	key	_
1-36	265-267	in	_
1-37	268-278	predicting	_
1-38	279-289	favourable	_
1-39	290-299	long-term	_
1-40	300-308	outcomes	_
1-41	309-310	.	_

Text=Following theoretical models of psychosis, this proof-of-concept study investigated whether the long-term recovery path of CBTp completers can be predicted by the neural changes in threat-based social affective processing that occur during CBTp.
2-1	311-320	Following	_
2-2	321-332	theoretical	_
2-3	333-339	models	_
2-4	340-342	of	_
2-5	343-352	psychosis	_
2-6	353-354	,	_
2-7	355-359	this	_
2-8	360-376	proof-of-concept	_
2-9	377-382	study	_
2-10	383-395	investigated	_
2-11	396-403	whether	_
2-12	404-407	the	_
2-13	408-417	long-term	_
2-14	418-426	recovery	_
2-15	427-431	path	_
2-16	432-434	of	_
2-17	435-439	CBTp	_
2-18	440-450	completers	_
2-19	451-454	can	_
2-20	455-457	be	_
2-21	458-467	predicted	_
2-22	468-470	by	_
2-23	471-474	the	_
2-24	475-481	neural	_
2-25	482-489	changes	_
2-26	490-492	in	_
2-27	493-505	threat-based	_
2-28	506-512	social	_
2-29	513-522	affective	_
2-30	523-533	processing	_
2-31	534-538	that	_
2-32	539-544	occur	_
2-33	545-551	during	_
2-34	552-556	CBTp	_
2-35	557-558	.	_

Text=We followed up 22 participants who had undergone a social affective processing task during functional magnetic resonance imaging along with self-report and clinician-administered symptom measures, before and after receiving CBTp.
3-1	559-561	We	_
3-2	562-570	followed	_
3-3	571-573	up	_
3-4	574-576	22	_
3-5	577-589	participants	_
3-6	590-593	who	_
3-7	594-597	had	_
3-8	598-607	undergone	_
3-9	608-609	a	_
3-10	610-616	social	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
3-11	617-626	affective	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
3-12	627-637	processing	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
3-13	638-642	task	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
3-14	643-649	during	_
3-15	650-660	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-16	661-669	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-17	670-679	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-18	680-687	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-19	688-693	along	_
3-20	694-698	with	_
3-21	699-710	self-report	_
3-22	711-714	and	_
3-23	715-737	clinician-administered	_
3-24	738-745	symptom	_
3-25	746-754	measures	_
3-26	755-756	,	_
3-27	757-763	before	_
3-28	764-767	and	_
3-29	768-773	after	_
3-30	774-783	receiving	_
3-31	784-788	CBTp	_
3-32	789-790	.	_

Text=Monthly ratings of psychotic and affective symptoms were obtained retrospectively across 8 years since receiving CBTp, plus self-reported recovery at final follow-up.
4-1	791-798	Monthly	_
4-2	799-806	ratings	_
4-3	807-809	of	_
4-4	810-819	psychotic	_
4-5	820-823	and	_
4-6	824-833	affective	_
4-7	834-842	symptoms	_
4-8	843-847	were	_
4-9	848-856	obtained	_
4-10	857-872	retrospectively	_
4-11	873-879	across	_
4-12	880-881	8	_
4-13	882-887	years	_
4-14	888-893	since	_
4-15	894-903	receiving	_
4-16	904-908	CBTp	_
4-17	909-910	,	_
4-18	911-915	plus	_
4-19	916-929	self-reported	_
4-20	930-938	recovery	_
4-21	939-941	at	_
4-22	942-947	final	_
4-23	948-957	follow-up	_
4-24	958-959	.	_

Text=We investigated whether these long-term outcomes were predicted by CBTp-led changes in functional connections with dorsal prefrontal cortical and amygdala during the processing of threatening and prosocial facial affect.
5-1	960-962	We	_
5-2	963-975	investigated	_
5-3	976-983	whether	_
5-4	984-989	these	_
5-5	990-999	long-term	_
5-6	1000-1008	outcomes	_
5-7	1009-1013	were	_
5-8	1014-1023	predicted	_
5-9	1024-1026	by	_
5-10	1027-1035	CBTp-led	_
5-11	1036-1043	changes	_
5-12	1044-1046	in	_
5-13	1047-1057	functional	_
5-14	1058-1069	connections	_
5-15	1070-1074	with	_
5-16	1075-1081	dorsal	_
5-17	1082-1092	prefrontal	_
5-18	1093-1101	cortical	_
5-19	1102-1105	and	_
5-20	1106-1114	amygdala	_
5-21	1115-1121	during	_
5-22	1122-1125	the	_
5-23	1126-1136	processing	_
5-24	1137-1139	of	_
5-25	1140-1151	threatening	_
5-26	1152-1155	and	_
5-27	1156-1165	prosocial	_
5-28	1166-1172	facial	_
5-29	1173-1179	affect	_
5-30	1180-1181	.	_

Text=Although long-term psychotic symptoms were predicted by changes in prefrontal connections during prosocial facial affective processing, long-term affective symptoms were predicted by threat-related amygdalo-inferior parietal lobule connectivity.
6-1	1182-1190	Although	_
6-2	1191-1200	long-term	_
6-3	1201-1210	psychotic	_
6-4	1211-1219	symptoms	_
6-5	1220-1224	were	_
6-6	1225-1234	predicted	_
6-7	1235-1237	by	_
6-8	1238-1245	changes	_
6-9	1246-1248	in	_
6-10	1249-1259	prefrontal	_
6-11	1260-1271	connections	_
6-12	1272-1278	during	_
6-13	1279-1288	prosocial	_
6-14	1289-1295	facial	_
6-15	1296-1305	affective	_
6-16	1306-1316	processing	_
6-17	1317-1318	,	_
6-18	1319-1328	long-term	_
6-19	1329-1338	affective	_
6-20	1339-1347	symptoms	_
6-21	1348-1352	were	_
6-22	1353-1362	predicted	_
6-23	1363-1365	by	_
6-24	1366-1380	threat-related	_
6-25	1381-1398	amygdalo-inferior	_
6-26	1399-1407	parietal	_
6-27	1408-1414	lobule	_
6-28	1415-1427	connectivity	_
6-29	1428-1429	.	_

Text=Greater increases in dorsolateral prefrontal cortex connectivity with amygdala following CBTp also predicted higher subjective ratings of recovery at long-term follow-up.
7-1	1430-1437	Greater	_
7-2	1438-1447	increases	_
7-3	1448-1450	in	_
7-4	1451-1463	dorsolateral	_
7-5	1464-1474	prefrontal	_
7-6	1475-1481	cortex	_
7-7	1482-1494	connectivity	_
7-8	1495-1499	with	_
7-9	1500-1508	amygdala	_
7-10	1509-1518	following	_
7-11	1519-1523	CBTp	_
7-12	1524-1528	also	_
7-13	1529-1538	predicted	_
7-14	1539-1545	higher	_
7-15	1546-1556	subjective	_
7-16	1557-1564	ratings	_
7-17	1565-1567	of	_
7-18	1568-1576	recovery	_
7-19	1577-1579	at	_
7-20	1580-1589	long-term	_
7-21	1590-1599	follow-up	_
7-22	1600-1601	.	_

Text=These findings show that reorganisation occurring at the neural level following psychological therapy can predict the subsequent recovery path of people with psychosis across 8 years.
8-1	1602-1607	These	_
8-2	1608-1616	findings	_
8-3	1617-1621	show	_
8-4	1622-1626	that	_
8-5	1627-1641	reorganisation	_
8-6	1642-1651	occurring	_
8-7	1652-1654	at	_
8-8	1655-1658	the	_
8-9	1659-1665	neural	_
8-10	1666-1671	level	_
8-11	1672-1681	following	_
8-12	1682-1695	psychological	_
8-13	1696-1703	therapy	_
8-14	1704-1707	can	_
8-15	1708-1715	predict	_
8-16	1716-1719	the	_
8-17	1720-1730	subsequent	_
8-18	1731-1739	recovery	_
8-19	1740-1744	path	_
8-20	1745-1747	of	_
8-21	1748-1754	people	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
8-22	1755-1759	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
8-23	1760-1769	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
8-24	1770-1776	across	_
8-25	1777-1778	8	_
8-26	1779-1784	years	_
8-27	1785-1786	.	_

Text=This novel methodology shows promise for further studies with larger sample size, which are needed to better examine the sensitivity of psychobiological processes, in comparison to existing clinical measures, in predicting long-term outcomes.
9-1	1787-1791	This	_
9-2	1792-1797	novel	_
9-3	1798-1809	methodology	_
9-4	1810-1815	shows	_
9-5	1816-1823	promise	_
9-6	1824-1827	for	_
9-7	1828-1835	further	_
9-8	1836-1843	studies	_
9-9	1844-1848	with	_
9-10	1849-1855	larger	_
9-11	1856-1862	sample	_
9-12	1863-1867	size	_
9-13	1868-1869	,	_
9-14	1870-1875	which	_
9-15	1876-1879	are	_
9-16	1880-1886	needed	_
9-17	1887-1889	to	_
9-18	1890-1896	better	_
9-19	1897-1904	examine	_
9-20	1905-1908	the	_
9-21	1909-1920	sensitivity	_
9-22	1921-1923	of	_
9-23	1924-1940	psychobiological	_
9-24	1941-1950	processes	_
9-25	1951-1952	,	_
9-26	1953-1955	in	_
9-27	1956-1966	comparison	_
9-28	1967-1969	to	_
9-29	1970-1978	existing	_
9-30	1979-1987	clinical	_
9-31	1988-1996	measures	_
9-32	1997-1998	,	_
9-33	1999-2001	in	_
9-34	2002-2012	predicting	_
9-35	2013-2022	long-term	_
9-36	2023-2031	outcomes	_
9-37	2032-2033	.	_

Text=Materials and Methods Participants and design Participants were 22 outpatients with a confirmed diagnosis of paranoid schizophrenia (final N=15; see Table 1) who had taken part in our earlier studies.
10-1	2034-2043	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	2044-2047	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	2048-2055	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	2056-2068	Participants	_
10-5	2069-2072	and	_
10-6	2073-2079	design	_
10-7	2080-2092	Participants	_
10-8	2093-2097	were	_
10-9	2098-2100	22	_
10-10	2101-2112	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
10-11	2113-2117	with	_
10-12	2118-2119	a	_
10-13	2120-2129	confirmed	_
10-14	2130-2139	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#ParanoidSchizophrenia
10-15	2140-2142	of	http://maven.renci.org/NeuroBridge/neurobridge#ParanoidSchizophrenia
10-16	2143-2151	paranoid	http://maven.renci.org/NeuroBridge/neurobridge#ParanoidSchizophrenia
10-17	2152-2165	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ParanoidSchizophrenia
10-18	2166-2167	(	_
10-19	2168-2173	final	_
10-20	2174-2178	N=15	_
10-21	2179-2180	;	_
10-22	2181-2184	see	_
10-23	2185-2190	Table	_
10-24	2191-2192	1	_
10-25	2193-2194	)	_
10-26	2195-2198	who	_
10-27	2199-2202	had	_
10-28	2203-2208	taken	_
10-29	2209-2213	part	_
10-30	2214-2216	in	_
10-31	2217-2220	our	_
10-32	2221-2228	earlier	_
10-33	2229-2236	studies	_
10-34	2237-2238	.	_

Text=These participants had completed an fMRI implicit facial affective processing task and a battery of clinical measures on two occasions, pre (T1) and post (T2) receiving 6 months of CBTp.
11-1	2239-2244	These	_
11-2	2245-2257	participants	_
11-3	2258-2261	had	_
11-4	2262-2271	completed	_
11-5	2272-2274	an	_
11-6	2275-2279	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-7	2280-2288	implicit	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-8	2289-2295	facial	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-9	2296-2305	affective	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-10	2306-2316	processing	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-11	2317-2321	task	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
11-12	2322-2325	and	_
11-13	2326-2327	a	_
11-14	2328-2335	battery	_
11-15	2336-2338	of	_
11-16	2339-2347	clinical	_
11-17	2348-2356	measures	_
11-18	2357-2359	on	_
11-19	2360-2363	two	_
11-20	2364-2373	occasions	_
11-21	2374-2375	,	_
11-22	2376-2379	pre	_
11-23	2380-2381	(	_
11-24	2382-2384	T1	_
11-25	2385-2386	)	_
11-26	2387-2390	and	_
11-27	2391-2395	post	_
11-28	2396-2397	(	_
11-29	2398-2400	T2	_
11-30	2401-2402	)	_
11-31	2403-2412	receiving	_
11-32	2413-2414	6	_
11-33	2415-2421	months	_
11-34	2422-2424	of	_
11-35	2425-2429	CBTp	_
11-36	2430-2431	.	_

Text=Sixteen outpatients receiving treatment-as-usual were also scanned at these time points (data not analysed as part of the present study).
12-1	2432-2439	Sixteen	_
12-2	2440-2451	outpatients	_
12-3	2452-2461	receiving	_
12-4	2462-2480	treatment-as-usual	_
12-5	2481-2485	were	_
12-6	2486-2490	also	_
12-7	2491-2498	scanned	_
12-8	2499-2501	at	_
12-9	2502-2507	these	_
12-10	2508-2512	time	_
12-11	2513-2519	points	_
12-12	2520-2521	(	_
12-13	2522-2526	data	_
12-14	2527-2530	not	_
12-15	2531-2539	analysed	_
12-16	2540-2542	as	_
12-17	2543-2547	part	_
12-18	2548-2550	of	_
12-19	2551-2554	the	_
12-20	2555-2562	present	_
12-21	2563-2568	study	_
12-22	2569-2570	)	_
12-23	2571-2572	.	_

Text=Procedure We retrospectively followed up these participants as their final fMRI scan (at T2), an average of 8 years (range 7–9 years) before the current study (T3).
13-1	2573-2582	Procedure	_
13-2	2583-2585	We	_
13-3	2586-2601	retrospectively	_
13-4	2602-2610	followed	_
13-5	2611-2613	up	_
13-6	2614-2619	these	_
13-7	2620-2632	participants	_
13-8	2633-2635	as	_
13-9	2636-2641	their	_
13-10	2642-2647	final	_
13-11	2648-2652	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
13-12	2653-2657	scan	_
13-13	2658-2659	(	_
13-14	2660-2662	at	_
13-15	2663-2665	T2	_
13-16	2666-2667	)	_
13-17	2668-2669	,	_
13-18	2670-2672	an	_
13-19	2673-2680	average	_
13-20	2681-2683	of	_
13-21	2684-2685	8	_
13-22	2686-2691	years	_
13-23	2692-2693	(	_
13-24	2694-2699	range	_
13-25	2700-2703	7–9	_
13-26	2704-2709	years	_
13-27	2710-2711	)	_
13-28	2712-2718	before	_
13-29	2719-2722	the	_
13-30	2723-2730	current	_
13-31	2731-2736	study	_
13-32	2737-2738	(	_
13-33	2739-2741	T3	_
13-34	2742-2743	)	_
13-35	2744-2745	.	_

Text=We obtained objective clinical outcomes for this entire period through case note review (T2 to T3; see Longitudinal Clinician Ratings) as well as current subjective ratings of recovery and well-being (at T3; see Outcome Measures).
14-1	2746-2748	We	_
14-2	2749-2757	obtained	_
14-3	2758-2767	objective	_
14-4	2768-2776	clinical	_
14-5	2777-2785	outcomes	_
14-6	2786-2789	for	_
14-7	2790-2794	this	_
14-8	2795-2801	entire	_
14-9	2802-2808	period	_
14-10	2809-2816	through	_
14-11	2817-2821	case	_
14-12	2822-2826	note	_
14-13	2827-2833	review	_
14-14	2834-2835	(	_
14-15	2836-2838	T2	_
14-16	2839-2841	to	_
14-17	2842-2844	T3	_
14-18	2845-2846	;	_
14-19	2847-2850	see	_
14-20	2851-2863	Longitudinal	_
14-21	2864-2873	Clinician	_
14-22	2874-2881	Ratings	_
14-23	2882-2883	)	_
14-24	2884-2886	as	_
14-25	2887-2891	well	_
14-26	2892-2894	as	_
14-27	2895-2902	current	_
14-28	2903-2913	subjective	_
14-29	2914-2921	ratings	_
14-30	2922-2924	of	_
14-31	2925-2933	recovery	_
14-32	2934-2937	and	_
14-33	2938-2948	well-being	_
14-34	2949-2950	(	_
14-35	2951-2953	at	_
14-36	2954-2956	T3	_
14-37	2957-2958	;	_
14-38	2959-2962	see	_
14-39	2963-2970	Outcome	_
14-40	2971-2979	Measures	_
14-41	2980-2981	)	_
14-42	2982-2983	.	_

Text=Consent was obtained by seeking current contact details from consultant clinicians in the services providing care for the previously recruited participants.
15-1	2984-2991	Consent	_
15-2	2992-2995	was	_
15-3	2996-3004	obtained	_
15-4	3005-3007	by	_
15-5	3008-3015	seeking	_
15-6	3016-3023	current	_
15-7	3024-3031	contact	_
15-8	3032-3039	details	_
15-9	3040-3044	from	_
15-10	3045-3055	consultant	_
15-11	3056-3066	clinicians	_
15-12	3067-3069	in	_
15-13	3070-3073	the	_
15-14	3074-3082	services	_
15-15	3083-3092	providing	_
15-16	3093-3097	care	_
15-17	3098-3101	for	_
15-18	3102-3105	the	_
15-19	3106-3116	previously	_
15-20	3117-3126	recruited	_
15-21	3127-3139	participants	_
15-22	3140-3141	.	_

Text=Participants were then contacted by phone and those expressing an interest received information about the study, a consent form for accessing their electronic clinic records, self-report questionnaires assessing well-being and recovery and a prepaid envelope.
16-1	3142-3154	Participants	_
16-2	3155-3159	were	_
16-3	3160-3164	then	_
16-4	3165-3174	contacted	_
16-5	3175-3177	by	_
16-6	3178-3183	phone	_
16-7	3184-3187	and	_
16-8	3188-3193	those	_
16-9	3194-3204	expressing	_
16-10	3205-3207	an	_
16-11	3208-3216	interest	_
16-12	3217-3225	received	_
16-13	3226-3237	information	_
16-14	3238-3243	about	_
16-15	3244-3247	the	_
16-16	3248-3253	study	_
16-17	3254-3255	,	_
16-18	3256-3257	a	_
16-19	3258-3265	consent	_
16-20	3266-3270	form	_
16-21	3271-3274	for	_
16-22	3275-3284	accessing	_
16-23	3285-3290	their	_
16-24	3291-3301	electronic	_
16-25	3302-3308	clinic	_
16-26	3309-3316	records	_
16-27	3317-3318	,	_
16-28	3319-3330	self-report	_
16-29	3331-3345	questionnaires	_
16-30	3346-3355	assessing	_
16-31	3356-3366	well-being	_
16-32	3367-3370	and	_
16-33	3371-3379	recovery	_
16-34	3380-3383	and	_
16-35	3384-3385	a	_
16-36	3386-3393	prepaid	_
16-37	3394-3402	envelope	_
16-38	3403-3404	.	_

Text=The final sample of participants who consented and returned the questionnaires were reimbursed £10 for their time.
17-1	3405-3408	The	_
17-2	3409-3414	final	_
17-3	3415-3421	sample	_
17-4	3422-3424	of	_
17-5	3425-3437	participants	_
17-6	3438-3441	who	_
17-7	3442-3451	consented	_
17-8	3452-3455	and	_
17-9	3456-3464	returned	_
17-10	3465-3468	the	_
17-11	3469-3483	questionnaires	_
17-12	3484-3488	were	_
17-13	3489-3499	reimbursed	_
17-14	3500-3503	£10	_
17-15	3504-3507	for	_
17-16	3508-3513	their	_
17-17	3514-3518	time	_
17-18	3519-3520	.	_

Text=Ethical approval was granted by the National Health Service research ethics committee (reference: 14/LO/0325).
18-1	3521-3528	Ethical	_
18-2	3529-3537	approval	_
18-3	3538-3541	was	_
18-4	3542-3549	granted	_
18-5	3550-3552	by	_
18-6	3553-3556	the	_
18-7	3557-3565	National	_
18-8	3566-3572	Health	_
18-9	3573-3580	Service	_
18-10	3581-3589	research	_
18-11	3590-3596	ethics	_
18-12	3597-3606	committee	_
18-13	3607-3608	(	_
18-14	3609-3618	reference	_
18-15	3619-3620	:	_
18-16	3621-3631	14/LO/0325	_
18-17	3632-3633	)	_
18-18	3634-3635	.	_

Text=Functional neuroimaging procedure As described in earlier reports, participants were presented with monochrome faces depicting fear, anger, happiness or neutral expressions, and had to indicate the sex of the face with a button press response.
19-1	3636-3646	Functional	_
19-2	3647-3659	neuroimaging	_
19-3	3660-3669	procedure	_
19-4	3670-3672	As	_
19-5	3673-3682	described	_
19-6	3683-3685	in	_
19-7	3686-3693	earlier	_
19-8	3694-3701	reports	_
19-9	3702-3703	,	_
19-10	3704-3716	participants	_
19-11	3717-3721	were	_
19-12	3722-3731	presented	_
19-13	3732-3736	with	_
19-14	3737-3747	monochrome	_
19-15	3748-3753	faces	_
19-16	3754-3763	depicting	_
19-17	3764-3768	fear	_
19-18	3769-3770	,	_
19-19	3771-3776	anger	_
19-20	3777-3778	,	_
19-21	3779-3788	happiness	_
19-22	3789-3791	or	_
19-23	3792-3799	neutral	_
19-24	3800-3811	expressions	_
19-25	3812-3813	,	_
19-26	3814-3817	and	_
19-27	3818-3821	had	_
19-28	3822-3824	to	_
19-29	3825-3833	indicate	_
19-30	3834-3837	the	_
19-31	3838-3841	sex	_
19-32	3842-3844	of	_
19-33	3845-3848	the	_
19-34	3849-3853	face	_
19-35	3854-3858	with	_
19-36	3859-3860	a	_
19-37	3861-3867	button	_
19-38	3868-3873	press	_
19-39	3874-3882	response	_
19-40	3883-3884	.	_

Text=These were repeated in four blocks per condition, with counterbalancing across 16 blocks (see Mason et al.
20-1	3885-3890	These	_
20-2	3891-3895	were	_
20-3	3896-3904	repeated	_
20-4	3905-3907	in	_
20-5	3908-3912	four	_
20-6	3913-3919	blocks	_
20-7	3920-3923	per	_
20-8	3924-3933	condition	_
20-9	3934-3935	,	_
20-10	3936-3940	with	_
20-11	3941-3957	counterbalancing	_
20-12	3958-3964	across	_
20-13	3965-3967	16	_
20-14	3968-3974	blocks	_
20-15	3975-3976	(	_
20-16	3977-3980	see	_
20-17	3981-3986	Mason	_
20-18	3987-3989	et	_
20-19	3990-3992	al	_
20-20	3993-3994	.	_

Text=and Supplementary Material for further details of the scanning protocol).
21-1	3995-3998	and	_
21-2	3999-4012	Supplementary	_
21-3	4013-4021	Material	_
21-4	4022-4025	for	_
21-5	4026-4033	further	_
21-6	4034-4041	details	_
21-7	4042-4044	of	_
21-8	4045-4048	the	_
21-9	4049-4057	scanning	_
21-10	4058-4066	protocol	_
21-11	4067-4068	)	_
21-12	4069-4070	.	_

Text=Changes in functional connectivity from T1 to T2 were quantified during social threat (angry faces) and prosocial social affect (happy faces) using the psychophysiological interaction approach.
22-1	4071-4078	Changes	_
22-2	4079-4081	in	_
22-3	4082-4092	functional	_
22-4	4093-4105	connectivity	_
22-5	4106-4110	from	_
22-6	4111-4113	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-7	4114-4116	to	_
22-8	4117-4119	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
22-9	4120-4124	were	_
22-10	4125-4135	quantified	_
22-11	4136-4142	during	_
22-12	4143-4149	social	_
22-13	4150-4156	threat	_
22-14	4157-4158	(	_
22-15	4159-4164	angry	_
22-16	4165-4170	faces	_
22-17	4171-4172	)	_
22-18	4173-4176	and	_
22-19	4177-4186	prosocial	_
22-20	4187-4193	social	_
22-21	4194-4200	affect	_
22-22	4201-4202	(	_
22-23	4203-4208	happy	_
22-24	4209-4214	faces	_
22-25	4215-4216	)	_
22-26	4217-4222	using	_
22-27	4223-4226	the	_
22-28	4227-4246	psychophysiological	_
22-29	4247-4258	interaction	_
22-30	4259-4267	approach	_
22-31	4268-4269	.	_

Text=Seeds were left amygdala and right DLPFC; whereas bilateral activation was found, we selected the regions of maximum task activation that were reported previously.
23-1	4270-4275	Seeds	_
23-2	4276-4280	were	_
23-3	4281-4285	left	_
23-4	4286-4294	amygdala	_
23-5	4295-4298	and	_
23-6	4299-4304	right	_
23-7	4305-4310	DLPFC	_
23-8	4311-4312	;	_
23-9	4313-4320	whereas	_
23-10	4321-4330	bilateral	_
23-11	4331-4341	activation	_
23-12	4342-4345	was	_
23-13	4346-4351	found	_
23-14	4352-4353	,	_
23-15	4354-4356	we	_
23-16	4357-4365	selected	_
23-17	4366-4369	the	_
23-18	4370-4377	regions	_
23-19	4378-4380	of	_
23-20	4381-4388	maximum	_
23-21	4389-4393	task	_
23-22	4394-4404	activation	_
23-23	4405-4409	that	_
23-24	4410-4414	were	_
23-25	4415-4423	reported	_
23-26	4424-4434	previously	_
23-27	4435-4436	.	_

Text=Seeds were defined functionally from the group-level maxima, with spheres around these maxima (3 and 4 mm radius for amygdala and DLPFC, respectively).
24-1	4437-4442	Seeds	_
24-2	4443-4447	were	_
24-3	4448-4455	defined	_
24-4	4456-4468	functionally	_
24-5	4469-4473	from	_
24-6	4474-4477	the	_
24-7	4478-4489	group-level	_
24-8	4490-4496	maxima	_
24-9	4497-4498	,	_
24-10	4499-4503	with	_
24-11	4504-4511	spheres	_
24-12	4512-4518	around	_
24-13	4519-4524	these	_
24-14	4525-4531	maxima	_
24-15	4532-4533	(	_
24-16	4534-4535	3	_
24-17	4536-4539	and	_
24-18	4540-4541	4	_
24-19	4542-4544	mm	_
24-20	4545-4551	radius	_
24-21	4552-4555	for	_
24-22	4556-4564	amygdala	_
24-23	4565-4568	and	_
24-24	4569-4574	DLPFC	_
24-25	4575-4576	,	_
24-26	4577-4589	respectively	_
24-27	4590-4591	)	_
24-28	4592-4593	.	_

Text=These were additionally constrained within anatomical masks for these regions as defined by the PickAtlas toolbox.
25-1	4594-4599	These	_
25-2	4600-4604	were	_
25-3	4605-4617	additionally	_
25-4	4618-4629	constrained	_
25-5	4630-4636	within	_
25-6	4637-4647	anatomical	_
25-7	4648-4653	masks	_
25-8	4654-4657	for	_
25-9	4658-4663	these	_
25-10	4664-4671	regions	_
25-11	4672-4674	as	_
25-12	4675-4682	defined	_
25-13	4683-4685	by	_
25-14	4686-4689	the	_
25-15	4690-4699	PickAtlas	_
25-16	4700-4707	toolbox	_
25-17	4708-4709	.	_

Text=Significant connectivity changes following CBTp were tested by examining the interaction of group (CBTp vs treatment-as-usual) by time (T1 vs T2).
26-1	4710-4721	Significant	_
26-2	4722-4734	connectivity	_
26-3	4735-4742	changes	_
26-4	4743-4752	following	_
26-5	4753-4757	CBTp	_
26-6	4758-4762	were	_
26-7	4763-4769	tested	_
26-8	4770-4772	by	_
26-9	4773-4782	examining	_
26-10	4783-4786	the	_
26-11	4787-4798	interaction	_
26-12	4799-4801	of	_
26-13	4802-4807	group	_
26-14	4808-4809	(	_
26-15	4810-4814	CBTp	_
26-16	4815-4817	vs	_
26-17	4818-4836	treatment-as-usual	_
26-18	4837-4838	)	_
26-19	4839-4841	by	_
26-20	4842-4846	time	_
26-21	4847-4848	(	_
26-22	4849-4851	T1	_
26-23	4852-4854	vs	_
26-24	4855-4857	T2	_
26-25	4858-4859	)	_
26-26	4860-4861	.	_

Text=There were exclusively increases in connectivity in the CBTp group across functional connections with amygdala and DLPFC.
27-1	4862-4867	There	_
27-2	4868-4872	were	_
27-3	4873-4884	exclusively	_
27-4	4885-4894	increases	_
27-5	4895-4897	in	_
27-6	4898-4910	connectivity	_
27-7	4911-4913	in	_
27-8	4914-4917	the	_
27-9	4918-4922	CBTp	_
27-10	4923-4928	group	_
27-11	4929-4935	across	_
27-12	4936-4946	functional	_
27-13	4947-4958	connections	_
27-14	4959-4963	with	_
27-15	4964-4972	amygdala	_
27-16	4973-4976	and	_
27-17	4977-4982	DLPFC	_
27-18	4983-4984	.	_

Text=For the present study, we focused our analyses on the change in DLPFC-amygdala connectivity that occurred during social threat processing, because of the strong theoretical link with cognitive regulation of affect and in turn the relevance to cognitive behavioural models of positive symptoms of psychosis.
28-1	4985-4988	For	_
28-2	4989-4992	the	_
28-3	4993-5000	present	_
28-4	5001-5006	study	_
28-5	5007-5008	,	_
28-6	5009-5011	we	_
28-7	5012-5019	focused	_
28-8	5020-5023	our	_
28-9	5024-5032	analyses	_
28-10	5033-5035	on	_
28-11	5036-5039	the	_
28-12	5040-5046	change	_
28-13	5047-5049	in	_
28-14	5050-5064	DLPFC-amygdala	_
28-15	5065-5077	connectivity	_
28-16	5078-5082	that	_
28-17	5083-5091	occurred	_
28-18	5092-5098	during	_
28-19	5099-5105	social	_
28-20	5106-5112	threat	_
28-21	5113-5123	processing	_
28-22	5124-5125	,	_
28-23	5126-5133	because	_
28-24	5134-5136	of	_
28-25	5137-5140	the	_
28-26	5141-5147	strong	_
28-27	5148-5159	theoretical	_
28-28	5160-5164	link	_
28-29	5165-5169	with	_
28-30	5170-5179	cognitive	_
28-31	5180-5190	regulation	_
28-32	5191-5193	of	_
28-33	5194-5200	affect	_
28-34	5201-5204	and	_
28-35	5205-5207	in	_
28-36	5208-5212	turn	_
28-37	5213-5216	the	_
28-38	5217-5226	relevance	_
28-39	5227-5229	to	_
28-40	5230-5239	cognitive	_
28-41	5240-5251	behavioural	_
28-42	5252-5258	models	_
28-43	5259-5261	of	_
28-44	5262-5270	positive	_
28-45	5271-5279	symptoms	_
28-46	5280-5282	of	_
28-47	5283-5292	psychosis	_
28-48	5293-5294	.	_

Text=We also included the two connectivity changes that previously correlated with improvement in positive psychotic symptoms: amygdala-IPL and DLPFC-postcentral gyrus, which had occurred for the processing of threat and prosocial facial affect, respectively.
29-1	5295-5297	We	_
29-2	5298-5302	also	_
29-3	5303-5311	included	_
29-4	5312-5315	the	_
29-5	5316-5319	two	_
29-6	5320-5332	connectivity	_
29-7	5333-5340	changes	_
29-8	5341-5345	that	_
29-9	5346-5356	previously	_
29-10	5357-5367	correlated	_
29-11	5368-5372	with	_
29-12	5373-5384	improvement	_
29-13	5385-5387	in	_
29-14	5388-5396	positive	_
29-15	5397-5406	psychotic	_
29-16	5407-5415	symptoms	_
29-17	5416-5417	:	_
29-18	5418-5430	amygdala-IPL	_
29-19	5431-5434	and	_
29-20	5435-5452	DLPFC-postcentral	_
29-21	5453-5458	gyrus	_
29-22	5459-5460	,	_
29-23	5461-5466	which	_
29-24	5467-5470	had	_
29-25	5471-5479	occurred	_
29-26	5480-5483	for	_
29-27	5484-5487	the	_
29-28	5488-5498	processing	_
29-29	5499-5501	of	_
29-30	5502-5508	threat	_
29-31	5509-5512	and	_
29-32	5513-5522	prosocial	_
29-33	5523-5529	facial	_
29-34	5530-5536	affect	_
29-35	5537-5538	,	_
29-36	5539-5551	respectively	_
29-37	5552-5553	.	_

Text=Cross-sectional clinical measures The following clinician-administered and self-report measures had previously been administered pre- and post- CBTp (T1 and T2).
30-1	5554-5569	Cross-sectional	_
30-2	5570-5578	clinical	_
30-3	5579-5587	measures	_
30-4	5588-5591	The	_
30-5	5592-5601	following	_
30-6	5602-5624	clinician-administered	_
30-7	5625-5628	and	_
30-8	5629-5640	self-report	_
30-9	5641-5649	measures	_
30-10	5650-5653	had	_
30-11	5654-5664	previously	_
30-12	5665-5669	been	_
30-13	5670-5682	administered	_
30-14	5683-5687	pre-	_
30-15	5688-5691	and	_
30-16	5692-5697	post-	_
30-17	5698-5702	CBTp	_
30-18	5703-5704	(	_
30-19	5705-5707	T1	_
30-20	5708-5711	and	_
30-21	5712-5714	T2	_
30-22	5715-5716	)	_
30-23	5717-5718	.	_

Text=The Positive and Negative Syndrome Schedule (PANSS); is a clinician-administered rating of positive, negative and general psychopathology symptoms.
31-1	5719-5722	The	_
31-2	5723-5731	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-3	5732-5735	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-4	5736-5744	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-5	5745-5753	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-6	5754-5762	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-7	5763-5764	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-8	5765-5770	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-9	5771-5772	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
31-10	5773-5774	;	_
31-11	5775-5777	is	_
31-12	5778-5779	a	_
31-13	5780-5802	clinician-administered	_
31-14	5803-5809	rating	_
31-15	5810-5812	of	_
31-16	5813-5821	positive	_
31-17	5822-5823	,	_
31-18	5824-5832	negative	_
31-19	5833-5836	and	_
31-20	5837-5844	general	_
31-21	5845-5860	psychopathology	_
31-22	5861-5869	symptoms	_
31-23	5870-5871	.	_

Text=Affective symptoms were measured from the Beck Depression Inventory, second edition.
32-1	5872-5881	Affective	_
32-2	5882-5890	symptoms	_
32-3	5891-5895	were	_
32-4	5896-5904	measured	_
32-5	5905-5909	from	_
32-6	5910-5913	the	_
32-7	5914-5918	Beck	_
32-8	5919-5929	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
32-9	5930-5939	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
32-10	5940-5941	,	_
32-11	5942-5948	second	_
32-12	5949-5956	edition	_
32-13	5957-5958	.	_

Text=We acquired additional measures at long-term follow-up (T3).
33-1	5959-5961	We	_
33-2	5962-5970	acquired	_
33-3	5971-5981	additional	_
33-4	5982-5990	measures	_
33-5	5991-5993	at	_
33-6	5994-6003	long-term	_
33-7	6004-6013	follow-up	_
33-8	6014-6015	(	_
33-9	6016-6018	T3	_
33-10	6019-6020	)	_
33-11	6021-6022	.	_

Text=We assessed subjective recovery using the Questionnaire about the Process of Recovery (QPR,), a service-user led instrument that follows theoretical models of recovery and provides a measure of constructs such as hope, empowerment, confidence, connectedness to others.
34-1	6023-6025	We	_
34-2	6026-6034	assessed	_
34-3	6035-6045	subjective	_
34-4	6046-6054	recovery	_
34-5	6055-6060	using	_
34-6	6061-6064	the	_
34-7	6065-6078	Questionnaire	_
34-8	6079-6084	about	_
34-9	6085-6088	the	_
34-10	6089-6096	Process	_
34-11	6097-6099	of	_
34-12	6100-6108	Recovery	_
34-13	6109-6110	(	_
34-14	6111-6114	QPR	_
34-15	6115-6116	,	_
34-16	6117-6118	)	_
34-17	6119-6120	,	_
34-18	6121-6122	a	_
34-19	6123-6135	service-user	_
34-20	6136-6139	led	_
34-21	6140-6150	instrument	_
34-22	6151-6155	that	_
34-23	6156-6163	follows	_
34-24	6164-6175	theoretical	_
34-25	6176-6182	models	_
34-26	6183-6185	of	_
34-27	6186-6194	recovery	_
34-28	6195-6198	and	_
34-29	6199-6207	provides	_
34-30	6208-6209	a	_
34-31	6210-6217	measure	_
34-32	6218-6220	of	_
34-33	6221-6231	constructs	_
34-34	6232-6236	such	_
34-35	6237-6239	as	_
34-36	6240-6244	hope	_
34-37	6245-6246	,	_
34-38	6247-6258	empowerment	_
34-39	6259-6260	,	_
34-40	6261-6271	confidence	_
34-41	6272-6273	,	_
34-42	6274-6287	connectedness	_
34-43	6288-6290	to	_
34-44	6291-6297	others	_
34-45	6298-6299	.	_

Text=This was our primary measure as it has one of the best psychometric properties of recovery measures and can be expected to be relatively robust to fluctuations in clinical state, making it well suited to use a cross-sectional measurement of long-term outcome.
35-1	6300-6304	This	_
35-2	6305-6308	was	_
35-3	6309-6312	our	_
35-4	6313-6320	primary	_
35-5	6321-6328	measure	_
35-6	6329-6331	as	_
35-7	6332-6334	it	_
35-8	6335-6338	has	_
35-9	6339-6342	one	_
35-10	6343-6345	of	_
35-11	6346-6349	the	_
35-12	6350-6354	best	_
35-13	6355-6367	psychometric	_
35-14	6368-6378	properties	_
35-15	6379-6381	of	_
35-16	6382-6390	recovery	_
35-17	6391-6399	measures	_
35-18	6400-6403	and	_
35-19	6404-6407	can	_
35-20	6408-6410	be	_
35-21	6411-6419	expected	_
35-22	6420-6422	to	_
35-23	6423-6425	be	_
35-24	6426-6436	relatively	_
35-25	6437-6443	robust	_
35-26	6444-6446	to	_
35-27	6447-6459	fluctuations	_
35-28	6460-6462	in	_
35-29	6463-6471	clinical	_
35-30	6472-6477	state	_
35-31	6478-6479	,	_
35-32	6480-6486	making	_
35-33	6487-6489	it	_
35-34	6490-6494	well	_
35-35	6495-6501	suited	_
35-36	6502-6504	to	_
35-37	6505-6508	use	_
35-38	6509-6510	a	_
35-39	6511-6526	cross-sectional	_
35-40	6527-6538	measurement	_
35-41	6539-6541	of	_
35-42	6542-6551	long-term	_
35-43	6552-6559	outcome	_
35-44	6560-6561	.	_

Text=Additional measures for well-being, satisfaction and functioning were acquired (Supplementary Materials) but were not included in analyses because of missing observations, a high correlation with self-reported recovery and to reduce the number of analyses reported.
36-1	6562-6572	Additional	_
36-2	6573-6581	measures	_
36-3	6582-6585	for	_
36-4	6586-6596	well-being	_
36-5	6597-6598	,	_
36-6	6599-6611	satisfaction	_
36-7	6612-6615	and	_
36-8	6616-6627	functioning	_
36-9	6628-6632	were	_
36-10	6633-6641	acquired	_
36-11	6642-6643	(	_
36-12	6644-6657	Supplementary	_
36-13	6658-6667	Materials	_
36-14	6668-6669	)	_
36-15	6670-6673	but	_
36-16	6674-6678	were	_
36-17	6679-6682	not	_
36-18	6683-6691	included	_
36-19	6692-6694	in	_
36-20	6695-6703	analyses	_
36-21	6704-6711	because	_
36-22	6712-6714	of	_
36-23	6715-6722	missing	_
36-24	6723-6735	observations	_
36-25	6736-6737	,	_
36-26	6738-6739	a	_
36-27	6740-6744	high	_
36-28	6745-6756	correlation	_
36-29	6757-6761	with	_
36-30	6762-6775	self-reported	_
36-31	6776-6784	recovery	_
36-32	6785-6788	and	_
36-33	6789-6791	to	_
36-34	6792-6798	reduce	_
36-35	6799-6802	the	_
36-36	6803-6809	number	_
36-37	6810-6812	of	_
36-38	6813-6821	analyses	_
36-39	6822-6830	reported	_
36-40	6831-6832	.	_

Text=These data are available on request from the first author.
37-1	6833-6838	These	_
37-2	6839-6843	data	_
37-3	6844-6847	are	_
37-4	6848-6857	available	_
37-5	6858-6860	on	_
37-6	6861-6868	request	_
37-7	6869-6873	from	_
37-8	6874-6877	the	_
37-9	6878-6883	first	_
37-10	6884-6890	author	_
37-11	6891-6892	.	_

Text=Longitudinal clinician ratings of symptoms: We retrospectively determined symptoms and functioning from electronic case note data held by local National Health Service trusts in South London.
38-1	6893-6905	Longitudinal	_
38-2	6906-6915	clinician	_
38-3	6916-6923	ratings	_
38-4	6924-6926	of	_
38-5	6927-6935	symptoms	_
38-6	6936-6937	:	_
38-7	6938-6940	We	_
38-8	6941-6956	retrospectively	_
38-9	6957-6967	determined	_
38-10	6968-6976	symptoms	_
38-11	6977-6980	and	_
38-12	6981-6992	functioning	_
38-13	6993-6997	from	_
38-14	6998-7008	electronic	_
38-15	7009-7013	case	_
38-16	7014-7018	note	_
38-17	7019-7023	data	_
38-18	7024-7028	held	_
38-19	7029-7031	by	_
38-20	7032-7037	local	_
38-21	7038-7046	National	_
38-22	7047-7053	Health	_
38-23	7054-7061	Service	_
38-24	7062-7068	trusts	_
38-25	7069-7071	in	_
38-26	7072-7077	South	_
38-27	7078-7084	London	_
38-28	7085-7086	.	_

Text=This covered the entire period between participants ’ final fMRI measurements (T2; circa 2007) and January 2015 (T3).
39-1	7087-7091	This	_
39-2	7092-7099	covered	_
39-3	7100-7103	the	_
39-4	7104-7110	entire	_
39-5	7111-7117	period	_
39-6	7118-7125	between	_
39-7	7126-7138	participants	_
39-8	7139-7140	’	_
39-9	7141-7146	final	_
39-10	7147-7151	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-11	7152-7164	measurements	_
39-12	7165-7166	(	_
39-13	7167-7169	T2	_
39-14	7170-7171	;	_
39-15	7172-7177	circa	_
39-16	7178-7182	2007	_
39-17	7183-7184	)	_
39-18	7185-7188	and	_
39-19	7189-7196	January	_
39-20	7197-7201	2015	_
39-21	7202-7203	(	_
39-22	7204-7206	T3	_
39-23	7207-7208	)	_
39-24	7209-7210	.	_

Text=Two raters followed validated operationalised criteria to infer presence of positive psychotic symptoms for each month independently, based on clinical note entries made by mental health professionals.
40-1	7211-7214	Two	_
40-2	7215-7221	raters	_
40-3	7222-7230	followed	_
40-4	7231-7240	validated	_
40-5	7241-7256	operationalised	_
40-6	7257-7265	criteria	_
40-7	7266-7268	to	_
40-8	7269-7274	infer	_
40-9	7275-7283	presence	_
40-10	7284-7286	of	_
40-11	7287-7295	positive	_
40-12	7296-7305	psychotic	_
40-13	7306-7314	symptoms	_
40-14	7315-7318	for	_
40-15	7319-7323	each	_
40-16	7324-7329	month	_
40-17	7330-7343	independently	_
40-18	7344-7345	,	_
40-19	7346-7351	based	_
40-20	7352-7354	on	_
40-21	7355-7363	clinical	_
40-22	7364-7368	note	_
40-23	7369-7376	entries	_
40-24	7377-7381	made	_
40-25	7382-7384	by	_
40-26	7385-7391	mental	_
40-27	7392-7398	health	_
40-28	7399-7412	professionals	_
40-29	7413-7414	.	_

Text=Participants were rated as being in ‘ full remission ’ (no symptoms present), ‘ partial remission ’ (symptoms of low intensity or frequency with clinicians noting at least partial insight), or ‘ no remission ’ (moderate symptoms; see Bebbington et al.
41-1	7415-7427	Participants	_
41-2	7428-7432	were	_
41-3	7433-7438	rated	_
41-4	7439-7441	as	_
41-5	7442-7447	being	_
41-6	7448-7450	in	_
41-7	7451-7452	‘	_
41-8	7453-7457	full	_
41-9	7458-7467	remission	_
41-10	7468-7469	’	_
41-11	7470-7471	(	_
41-12	7472-7474	no	_
41-13	7475-7483	symptoms	_
41-14	7484-7491	present	_
41-15	7492-7493	)	_
41-16	7494-7495	,	_
41-17	7496-7497	‘	_
41-18	7498-7505	partial	_
41-19	7506-7515	remission	_
41-20	7516-7517	’	_
41-21	7518-7519	(	_
41-22	7520-7528	symptoms	_
41-23	7529-7531	of	_
41-24	7532-7535	low	_
41-25	7536-7545	intensity	_
41-26	7546-7548	or	_
41-27	7549-7558	frequency	_
41-28	7559-7563	with	_
41-29	7564-7574	clinicians	_
41-30	7575-7581	noting	_
41-31	7582-7584	at	_
41-32	7585-7590	least	_
41-33	7591-7598	partial	_
41-34	7599-7606	insight	_
41-35	7607-7608	)	_
41-36	7609-7610	,	_
41-37	7611-7613	or	_
41-38	7614-7615	‘	_
41-39	7616-7618	no	_
41-40	7619-7628	remission	_
41-41	7629-7630	’	_
41-42	7631-7632	(	_
41-43	7633-7641	moderate	_
41-44	7642-7650	symptoms	_
41-45	7651-7652	;	_
41-46	7653-7656	see	_
41-47	7657-7667	Bebbington	_
41-48	7668-7670	et	_
41-49	7671-7673	al	_
41-50	7674-7675	.	_

Text=for fully detailed criteria).
42-1	7676-7679	for	_
42-2	7680-7685	fully	_
42-3	7686-7694	detailed	_
42-4	7695-7703	criteria	_
42-5	7704-7705	)	_
42-6	7706-7707	.	_

Text=Ratings of affective symptoms were based on both the intensity and frequency of affective disturbance as follows.
43-1	7708-7715	Ratings	_
43-2	7716-7718	of	_
43-3	7719-7728	affective	_
43-4	7729-7737	symptoms	_
43-5	7738-7742	were	_
43-6	7743-7748	based	_
43-7	7749-7751	on	_
43-8	7752-7756	both	_
43-9	7757-7760	the	_
43-10	7761-7770	intensity	_
43-11	7771-7774	and	_
43-12	7775-7784	frequency	_
43-13	7785-7787	of	_
43-14	7788-7797	affective	_
43-15	7798-7809	disturbance	_
43-16	7810-7812	as	_
43-17	7813-7820	follows	_
43-18	7821-7822	.	_

Text=Affective symptoms were rated as ‘ low ’ when there was no indication of distress or only brief periods (<3 days, maximum of two separate instances for that month) of mild-to-moderate severity (without expression of suicidality and that did not require intervention by mental health professionals).
44-1	7823-7832	Affective	_
44-2	7833-7841	symptoms	_
44-3	7842-7846	were	_
44-4	7847-7852	rated	_
44-5	7853-7855	as	_
44-6	7856-7857	‘	_
44-7	7858-7861	low	_
44-8	7862-7863	’	_
44-9	7864-7868	when	_
44-10	7869-7874	there	_
44-11	7875-7878	was	_
44-12	7879-7881	no	_
44-13	7882-7892	indication	_
44-14	7893-7895	of	_
44-15	7896-7904	distress	_
44-16	7905-7907	or	_
44-17	7908-7912	only	_
44-18	7913-7918	brief	_
44-19	7919-7926	periods	_
44-20	7927-7928	(	_
44-21	7929-7930	<	_
44-22	7931-7932	3	_
44-23	7933-7937	days	_
44-24	7938-7939	,	_
44-25	7940-7947	maximum	_
44-26	7948-7950	of	_
44-27	7951-7954	two	_
44-28	7955-7963	separate	_
44-29	7964-7973	instances	_
44-30	7974-7977	for	_
44-31	7978-7982	that	_
44-32	7983-7988	month	_
44-33	7989-7990	)	_
44-34	7991-7993	of	_
44-35	7994-8010	mild-to-moderate	_
44-36	8011-8019	severity	_
44-37	8020-8021	(	_
44-38	8022-8029	without	_
44-39	8030-8040	expression	_
44-40	8041-8043	of	_
44-41	8044-8055	suicidality	_
44-42	8056-8059	and	_
44-43	8060-8064	that	_
44-44	8065-8068	did	_
44-45	8069-8072	not	_
44-46	8073-8080	require	_
44-47	8081-8093	intervention	_
44-48	8094-8096	by	_
44-49	8097-8103	mental	_
44-50	8104-8110	health	_
44-51	8111-8124	professionals	_
44-52	8125-8126	)	_
44-53	8127-8128	.	_

Text=‘ Moderate ’ affective symptoms was rated where there was any period of distress lasting more than 3 days, where there was expression of suicidality not requiring severe management, or where there were three or more instances of ‘ low ’ affective symptoms present for that month.
45-1	8129-8130	‘	_
45-2	8131-8139	Moderate	_
45-3	8140-8141	’	_
45-4	8142-8151	affective	_
45-5	8152-8160	symptoms	_
45-6	8161-8164	was	_
45-7	8165-8170	rated	_
45-8	8171-8176	where	_
45-9	8177-8182	there	_
45-10	8183-8186	was	_
45-11	8187-8190	any	_
45-12	8191-8197	period	_
45-13	8198-8200	of	_
45-14	8201-8209	distress	_
45-15	8210-8217	lasting	_
45-16	8218-8222	more	_
45-17	8223-8227	than	_
45-18	8228-8229	3	_
45-19	8230-8234	days	_
45-20	8235-8236	,	_
45-21	8237-8242	where	_
45-22	8243-8248	there	_
45-23	8249-8252	was	_
45-24	8253-8263	expression	_
45-25	8264-8266	of	_
45-26	8267-8278	suicidality	_
45-27	8279-8282	not	_
45-28	8283-8292	requiring	_
45-29	8293-8299	severe	_
45-30	8300-8310	management	_
45-31	8311-8312	,	_
45-32	8313-8315	or	_
45-33	8316-8321	where	_
45-34	8322-8327	there	_
45-35	8328-8332	were	_
45-36	8333-8338	three	_
45-37	8339-8341	or	_
45-38	8342-8346	more	_
45-39	8347-8356	instances	_
45-40	8357-8359	of	_
45-41	8360-8361	‘	_
45-42	8362-8365	low	_
45-43	8366-8367	’	_
45-44	8368-8377	affective	_
45-45	8378-8386	symptoms	_
45-46	8387-8394	present	_
45-47	8395-8398	for	_
45-48	8399-8403	that	_
45-49	8404-8409	month	_
45-50	8410-8411	.	_

Text=‘ Severe ’ was rated for any month in which there was severe distress and suicidality requiring severe management, including hospitalisation or home treatment care.
46-1	8412-8413	‘	_
46-2	8414-8420	Severe	_
46-3	8421-8422	’	_
46-4	8423-8426	was	_
46-5	8427-8432	rated	_
46-6	8433-8436	for	_
46-7	8437-8440	any	_
46-8	8441-8446	month	_
46-9	8447-8449	in	_
46-10	8450-8455	which	_
46-11	8456-8461	there	_
46-12	8462-8465	was	_
46-13	8466-8472	severe	_
46-14	8473-8481	distress	_
46-15	8482-8485	and	_
46-16	8486-8497	suicidality	_
46-17	8498-8507	requiring	_
46-18	8508-8514	severe	_
46-19	8515-8525	management	_
46-20	8526-8527	,	_
46-21	8528-8537	including	_
46-22	8538-8553	hospitalisation	_
46-23	8554-8556	or	_
46-24	8557-8561	home	_
46-25	8562-8571	treatment	_
46-26	8572-8576	care	_
46-27	8577-8578	.	_

Text=This method was shown to have high reliability and clinical validity, with strong associations between the ratings of symptoms made by case note ratings and PANSS in the same participants.
47-1	8579-8583	This	_
47-2	8584-8590	method	_
47-3	8591-8594	was	_
47-4	8595-8600	shown	_
47-5	8601-8603	to	_
47-6	8604-8608	have	_
47-7	8609-8613	high	_
47-8	8614-8625	reliability	_
47-9	8626-8629	and	_
47-10	8630-8638	clinical	_
47-11	8639-8647	validity	_
47-12	8648-8649	,	_
47-13	8650-8654	with	_
47-14	8655-8661	strong	_
47-15	8662-8674	associations	_
47-16	8675-8682	between	_
47-17	8683-8686	the	_
47-18	8687-8694	ratings	_
47-19	8695-8697	of	_
47-20	8698-8706	symptoms	_
47-21	8707-8711	made	_
47-22	8712-8714	by	_
47-23	8715-8719	case	_
47-24	8720-8724	note	_
47-25	8725-8732	ratings	_
47-26	8733-8736	and	_
47-27	8737-8742	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
47-28	8743-8745	in	_
47-29	8746-8749	the	_
47-30	8750-8754	same	_
47-31	8755-8767	participants	_
47-32	8768-8769	.	_

Text=We confirmed that reliability was also high for ratings made in the present study, with inter-rater agreement ranging from ‘ moderate ’ to ‘ almost perfect ’ (Supplementary Materials).
48-1	8770-8772	We	_
48-2	8773-8782	confirmed	_
48-3	8783-8787	that	_
48-4	8788-8799	reliability	_
48-5	8800-8803	was	_
48-6	8804-8808	also	_
48-7	8809-8813	high	_
48-8	8814-8817	for	_
48-9	8818-8825	ratings	_
48-10	8826-8830	made	_
48-11	8831-8833	in	_
48-12	8834-8837	the	_
48-13	8838-8845	present	_
48-14	8846-8851	study	_
48-15	8852-8853	,	_
48-16	8854-8858	with	_
48-17	8859-8870	inter-rater	_
48-18	8871-8880	agreement	_
48-19	8881-8888	ranging	_
48-20	8889-8893	from	_
48-21	8894-8895	‘	_
48-22	8896-8904	moderate	_
48-23	8905-8906	’	_
48-24	8907-8909	to	_
48-25	8910-8911	‘	_
48-26	8912-8918	almost	_
48-27	8919-8926	perfect	_
48-28	8927-8928	’	_
48-29	8929-8930	(	_
48-30	8931-8944	Supplementary	_
48-31	8945-8954	Materials	_
48-32	8955-8956	)	_
48-33	8957-8958	.	_

Text=In addition to these symptom ratings, we also rated level of care needed (categories: care of general practitioner only; outpatient appointments in secondary care; daily home treatment; hospital treatment) and occupational functioning (paid employment; voluntary work or training course; unemployed), as a mean of validating the clinical ratings (Supplementary Table 1).
49-1	8959-8961	In	_
49-2	8962-8970	addition	_
49-3	8971-8973	to	_
49-4	8974-8979	these	_
49-5	8980-8987	symptom	_
49-6	8988-8995	ratings	_
49-7	8996-8997	,	_
49-8	8998-9000	we	_
49-9	9001-9005	also	_
49-10	9006-9011	rated	_
49-11	9012-9017	level	_
49-12	9018-9020	of	_
49-13	9021-9025	care	_
49-14	9026-9032	needed	_
49-15	9033-9034	(	_
49-16	9035-9045	categories	_
49-17	9046-9047	:	_
49-18	9048-9052	care	_
49-19	9053-9055	of	_
49-20	9056-9063	general	_
49-21	9064-9076	practitioner	_
49-22	9077-9081	only	_
49-23	9082-9083	;	_
49-24	9084-9094	outpatient	_
49-25	9095-9107	appointments	_
49-26	9108-9110	in	_
49-27	9111-9120	secondary	_
49-28	9121-9125	care	_
49-29	9126-9127	;	_
49-30	9128-9133	daily	_
49-31	9134-9138	home	_
49-32	9139-9148	treatment	_
49-33	9149-9150	;	_
49-34	9151-9159	hospital	_
49-35	9160-9169	treatment	_
49-36	9170-9171	)	_
49-37	9172-9175	and	_
49-38	9176-9188	occupational	_
49-39	9189-9200	functioning	_
49-40	9201-9202	(	_
49-41	9203-9207	paid	_
49-42	9208-9218	employment	_
49-43	9219-9220	;	_
49-44	9221-9230	voluntary	_
49-45	9231-9235	work	_
49-46	9236-9238	or	_
49-47	9239-9247	training	_
49-48	9248-9254	course	_
49-49	9255-9256	;	_
49-50	9257-9267	unemployed	_
49-51	9268-9269	)	_
49-52	9270-9271	,	_
49-53	9272-9274	as	_
49-54	9275-9276	a	_
49-55	9277-9281	mean	_
49-56	9282-9284	of	_
49-57	9285-9295	validating	_
49-58	9296-9299	the	_
49-59	9300-9308	clinical	_
49-60	9309-9316	ratings	_
49-61	9317-9318	(	_
49-62	9319-9332	Supplementary	_
49-63	9333-9338	Table	_
49-64	9339-9340	1	_
49-65	9341-9342	)	_
49-66	9343-9344	.	_

Text=There were significant positive associations between the non-remission measure and amount of severe care (hospitalisation and home treatment; see Supplementary Table 2).
50-1	9345-9350	There	_
50-2	9351-9355	were	_
50-3	9356-9367	significant	_
50-4	9368-9376	positive	_
50-5	9377-9389	associations	_
50-6	9390-9397	between	_
50-7	9398-9401	the	_
50-8	9402-9415	non-remission	_
50-9	9416-9423	measure	_
50-10	9424-9427	and	_
50-11	9428-9434	amount	_
50-12	9435-9437	of	_
50-13	9438-9444	severe	_
50-14	9445-9449	care	_
50-15	9450-9451	(	_
50-16	9452-9467	hospitalisation	_
50-17	9468-9471	and	_
50-18	9472-9476	home	_
50-19	9477-9486	treatment	_
50-20	9487-9488	;	_
50-21	9489-9492	see	_
50-22	9493-9506	Supplementary	_
50-23	9507-9512	Table	_
50-24	9513-9514	2	_
50-25	9515-9516	)	_
50-26	9517-9518	.	_

Text=Data analysis Prediction of long-term outcomes from functional connectivity changes Multivariate analysis of variance (MANOVA, Wilk ’ s Lambda) was used to relate the longitudinal, month-by-month clinician ratings of psychotic and affective symptoms (T2 to T3) as well as subjective recovery (T3), to the functional connectivity changes (T1 to T2) as follows.
51-1	9519-9523	Data	_
51-2	9524-9532	analysis	_
51-3	9533-9543	Prediction	_
51-4	9544-9546	of	_
51-5	9547-9556	long-term	_
51-6	9557-9565	outcomes	_
51-7	9566-9570	from	_
51-8	9571-9581	functional	_
51-9	9582-9594	connectivity	_
51-10	9595-9602	changes	_
51-11	9603-9615	Multivariate	_
51-12	9616-9624	analysis	_
51-13	9625-9627	of	_
51-14	9628-9636	variance	_
51-15	9637-9638	(	_
51-16	9639-9645	MANOVA	_
51-17	9646-9647	,	_
51-18	9648-9652	Wilk	_
51-19	9653-9654	’	_
51-20	9655-9656	s	_
51-21	9657-9663	Lambda	_
51-22	9664-9665	)	_
51-23	9666-9669	was	_
51-24	9670-9674	used	_
51-25	9675-9677	to	_
51-26	9678-9684	relate	_
51-27	9685-9688	the	_
51-28	9689-9701	longitudinal	_
51-29	9702-9703	,	_
51-30	9704-9718	month-by-month	_
51-31	9719-9728	clinician	_
51-32	9729-9736	ratings	_
51-33	9737-9739	of	_
51-34	9740-9749	psychotic	_
51-35	9750-9753	and	_
51-36	9754-9763	affective	_
51-37	9764-9772	symptoms	_
51-38	9773-9774	(	_
51-39	9775-9777	T2	_
51-40	9778-9780	to	_
51-41	9781-9783	T3	_
51-42	9784-9785	)	_
51-43	9786-9788	as	_
51-44	9789-9793	well	_
51-45	9794-9796	as	_
51-46	9797-9807	subjective	_
51-47	9808-9816	recovery	_
51-48	9817-9818	(	_
51-49	9819-9821	T3	_
51-50	9822-9823	)	_
51-51	9824-9825	,	_
51-52	9826-9828	to	_
51-53	9829-9832	the	_
51-54	9833-9843	functional	_
51-55	9844-9856	connectivity	_
51-56	9857-9864	changes	_
51-57	9865-9866	(	_
51-58	9867-9869	T1	_
51-59	9870-9872	to	_
51-60	9873-9875	T2	_
51-61	9876-9877	)	_
51-62	9878-9880	as	_
51-63	9881-9888	follows	_
51-64	9889-9890	.	_

Text=All tests were performed one-tailed.
52-1	9891-9894	All	_
52-2	9895-9900	tests	_
52-3	9901-9905	were	_
52-4	9906-9915	performed	_
52-5	9916-9926	one-tailed	_
52-6	9927-9928	.	_

Text=Percentage of months spent in each of the three symptom states was computed for positive psychotic symptoms (full, partial or non-remission) and for affective symptoms (low, moderate or severe).
53-1	9929-9939	Percentage	_
53-2	9940-9942	of	_
53-3	9943-9949	months	_
53-4	9950-9955	spent	_
53-5	9956-9958	in	_
53-6	9959-9963	each	_
53-7	9964-9966	of	_
53-8	9967-9970	the	_
53-9	9971-9976	three	_
53-10	9977-9984	symptom	_
53-11	9985-9991	states	_
53-12	9992-9995	was	_
53-13	9996-10004	computed	_
53-14	10005-10008	for	_
53-15	10009-10017	positive	_
53-16	10018-10027	psychotic	_
53-17	10028-10036	symptoms	_
53-18	10037-10038	(	_
53-19	10039-10043	full	_
53-20	10044-10045	,	_
53-21	10046-10053	partial	_
53-22	10054-10056	or	_
53-23	10057-10070	non-remission	_
53-24	10071-10072	)	_
53-25	10073-10076	and	_
53-26	10077-10080	for	_
53-27	10081-10090	affective	_
53-28	10091-10099	symptoms	_
53-29	10100-10101	(	_
53-30	10102-10105	low	_
53-31	10106-10107	,	_
53-32	10108-10116	moderate	_
53-33	10117-10119	or	_
53-34	10120-10126	severe	_
53-35	10127-10128	)	_
53-36	10129-10130	.	_

Text=To simplify the analyses and to reduce model over-fitting, we computed a single residualised variable for each symptom domain (see Supplementary Materials for details).
54-1	10131-10133	To	_
54-2	10134-10142	simplify	_
54-3	10143-10146	the	_
54-4	10147-10155	analyses	_
54-5	10156-10159	and	_
54-6	10160-10162	to	_
54-7	10163-10169	reduce	_
54-8	10170-10175	model	_
54-9	10176-10188	over-fitting	_
54-10	10189-10190	,	_
54-11	10191-10193	we	_
54-12	10194-10202	computed	_
54-13	10203-10204	a	_
54-14	10205-10211	single	_
54-15	10212-10224	residualised	_
54-16	10225-10233	variable	_
54-17	10234-10237	for	_
54-18	10238-10242	each	_
54-19	10243-10250	symptom	_
54-20	10251-10257	domain	_
54-21	10258-10259	(	_
54-22	10260-10263	see	_
54-23	10264-10277	Supplementary	_
54-24	10278-10287	Materials	_
54-25	10288-10291	for	_
54-26	10292-10299	details	_
54-27	10300-10301	)	_
54-28	10302-10303	.	_

Text=The effect of psychotic and affective symptom domains was tested separately, by entering the respective symptom variable as a regressor within MANOVA, along with our hypothesised changes in connectivity as dependent variables.
55-1	10304-10307	The	_
55-2	10308-10314	effect	_
55-3	10315-10317	of	_
55-4	10318-10327	psychotic	_
55-5	10328-10331	and	_
55-6	10332-10341	affective	_
55-7	10342-10349	symptom	_
55-8	10350-10357	domains	_
55-9	10358-10361	was	_
55-10	10362-10368	tested	_
55-11	10369-10379	separately	_
55-12	10380-10381	,	_
55-13	10382-10384	by	_
55-14	10385-10393	entering	_
55-15	10394-10397	the	_
55-16	10398-10408	respective	_
55-17	10409-10416	symptom	_
55-18	10417-10425	variable	_
55-19	10426-10428	as	_
55-20	10429-10430	a	_
55-21	10431-10440	regressor	_
55-22	10441-10447	within	_
55-23	10448-10454	MANOVA	_
55-24	10455-10456	,	_
55-25	10457-10462	along	_
55-26	10463-10467	with	_
55-27	10468-10471	our	_
55-28	10472-10484	hypothesised	_
55-29	10485-10492	changes	_
55-30	10493-10495	in	_
55-31	10496-10508	connectivity	_
55-32	10509-10511	as	_
55-33	10512-10521	dependent	_
55-34	10522-10531	variables	_
55-35	10532-10533	.	_

Text=Bonferroni correction was applied for multiple tests (p/2) across the two symptom domains and significant effects were followed up using correlation tests (Spearman; rρ) to clarify the direction of associations.
56-1	10534-10544	Bonferroni	_
56-2	10545-10555	correction	_
56-3	10556-10559	was	_
56-4	10560-10567	applied	_
56-5	10568-10571	for	_
56-6	10572-10580	multiple	_
56-7	10581-10586	tests	_
56-8	10587-10588	(	_
56-9	10589-10592	p/2	_
56-10	10593-10594	)	_
56-11	10595-10601	across	_
56-12	10602-10605	the	_
56-13	10606-10609	two	_
56-14	10610-10617	symptom	_
56-15	10618-10625	domains	_
56-16	10626-10629	and	_
56-17	10630-10641	significant	_
56-18	10642-10649	effects	_
56-19	10650-10654	were	_
56-20	10655-10663	followed	_
56-21	10664-10666	up	_
56-22	10667-10672	using	_
56-23	10673-10684	correlation	_
56-24	10685-10690	tests	_
56-25	10691-10692	(	_
56-26	10693-10701	Spearman	_
56-27	10702-10703	;	_
56-28	10704-10706	rρ	_
56-29	10707-10708	)	_
56-30	10709-10711	to	_
56-31	10712-10719	clarify	_
56-32	10720-10723	the	_
56-33	10724-10733	direction	_
56-34	10734-10736	of	_
56-35	10737-10749	associations	_
56-36	10750-10751	.	_

Text=We also performed an exploratory analysis to address the hypothesis that the therapeutic effects of CBTp would be better captured by changes to core threat processes than by short-term symptom reduction.
57-1	10752-10754	We	_
57-2	10755-10759	also	_
57-3	10760-10769	performed	_
57-4	10770-10772	an	_
57-5	10773-10784	exploratory	_
57-6	10785-10793	analysis	_
57-7	10794-10796	to	_
57-8	10797-10804	address	_
57-9	10805-10808	the	_
57-10	10809-10819	hypothesis	_
57-11	10820-10824	that	_
57-12	10825-10828	the	_
57-13	10829-10840	therapeutic	_
57-14	10841-10848	effects	_
57-15	10849-10851	of	_
57-16	10852-10856	CBTp	_
57-17	10857-10862	would	_
57-18	10863-10865	be	_
57-19	10866-10872	better	_
57-20	10873-10881	captured	_
57-21	10882-10884	by	_
57-22	10885-10892	changes	_
57-23	10893-10895	to	_
57-24	10896-10900	core	_
57-25	10901-10907	threat	_
57-26	10908-10917	processes	_
57-27	10918-10922	than	_
57-28	10923-10925	by	_
57-29	10926-10936	short-term	_
57-30	10937-10944	symptom	_
57-31	10945-10954	reduction	_
57-32	10955-10956	.	_

Text=Because of the exploratory nature, this analysis is reported as Supplementary Material.
58-1	10957-10964	Because	_
58-2	10965-10967	of	_
58-3	10968-10971	the	_
58-4	10972-10983	exploratory	_
58-5	10984-10990	nature	_
58-6	10991-10992	,	_
58-7	10993-10997	this	_
58-8	10998-11006	analysis	_
58-9	11007-11009	is	_
58-10	11010-11018	reported	_
58-11	11019-11021	as	_
58-12	11022-11035	Supplementary	_
58-13	11036-11044	Material	_
58-14	11045-11046	.	_

Text=Finally, we separately tested the relationship between the functional connectivity changes and long-term subjective recovery, the total score of which was entered as a regressor into MANOVA with the functional connectivity changes as dependent variables.
59-1	11047-11054	Finally	_
59-2	11055-11056	,	_
59-3	11057-11059	we	_
59-4	11060-11070	separately	_
59-5	11071-11077	tested	_
59-6	11078-11081	the	_
59-7	11082-11094	relationship	_
59-8	11095-11102	between	_
59-9	11103-11106	the	_
59-10	11107-11117	functional	_
59-11	11118-11130	connectivity	_
59-12	11131-11138	changes	_
59-13	11139-11142	and	_
59-14	11143-11152	long-term	_
59-15	11153-11163	subjective	_
59-16	11164-11172	recovery	_
59-17	11173-11174	,	_
59-18	11175-11178	the	_
59-19	11179-11184	total	_
59-20	11185-11190	score	_
59-21	11191-11193	of	_
59-22	11194-11199	which	_
59-23	11200-11203	was	_
59-24	11204-11211	entered	_
59-25	11212-11214	as	_
59-26	11215-11216	a	_
59-27	11217-11226	regressor	_
59-28	11227-11231	into	_
59-29	11232-11238	MANOVA	_
59-30	11239-11243	with	_
59-31	11244-11247	the	_
59-32	11248-11258	functional	_
59-33	11259-11271	connectivity	_
59-34	11272-11279	changes	_
59-35	11280-11282	as	_
59-36	11283-11292	dependent	_
59-37	11293-11302	variables	_
59-38	11303-11304	.	_

